It is estimated that inherited retinal diseases (IRDs) affect roughly one in 2000 people worldwide, often beginning in childhood and leading to life-long visual impairment. Despite decades of research and numerous drug trials, effective treatments remain elusive for most patients.

In a recent outreach article published on Scientia (“Dr Henri Leinonen | Fighting Blindness with Drug Repurposing”), Dr. Henri Leinonen from the University of Eastern Finland shares how his laboratory is taking a fresh look at IRDs, not by chasing every rare genetic mutation, but by focusing on general disease pathways that are often most shared between distinct IRDs.

At the core of the lab’s approach is drug repurposing, that is, using existing, approved medicines in novel combinations to intervene in the degeneration process. Because IRDs stem from hundreds of different mutations, mutation-agnostic strategies are especially appealing. Leinonen’s team has focused on G protein-coupled receptor (GPCR) networks, intracellular calcium and cyclic AMP signaling, and the retina’s own homeostatic responses. Their triple-drug cocktail (tamsulosin, metoprolol, bromocriptine) showed durable protection across several preclinical models of IRD, while monotherapies fell short.

The Scientia article reflects the lab’s two-pronged focus:

  1. Understanding how the retina adapts or fails to adapt when photoreceptors are stressed 
  2. Turning that understanding into therapy: by stabilizing signaling networks and reducing cell stress culminating in faster degeneration

Leinonen emphasizes that drug repurposing offers several major advantages: shorter development timelines, well-understood safety profiles, and broader applicability across genetic variants. Combined with deep mechanistic insight into plasticity and signaling, the lab’s vision is a faster, more inclusive path to treatment.

For anyone tracking progress in retinal neuroprotection, this research signals a shift: from targeting each gene to empowering each nerve cell’s resilience. If successful, it may change how we approach degenerative processes.

You can read the full article on Scientia here.